Cargando…
CD20 Antibody Primes B Lymphocytes for Type I Interferon Production
CD20 is a B cell surface marker that is expressed in various stages in B lymphocytes and certain lymphomas. Clinical administration of CD20 antibody, such as rituximab, is used widely to treat human B-cell lymphomas and other diseases. However, CD20 antibody failed to treat systemic lupus erythemato...
Autores principales: | Xu, Dongsheng, Staedman, Andrew, Zhang, Luwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707517/ https://www.ncbi.nlm.nih.gov/pubmed/23874371 http://dx.doi.org/10.1371/journal.pone.0067900 |
Ejemplares similares
-
Dual Functions of Interferon Regulatory Factors 7C in Epstein-Barr Virus–Mediated Transformation of Human B Lymphocytes
por: Zhao, Yong, et al.
Publicado: (2010) -
Restoration of type I interferon signaling in intrahepatically primed CD8(+) T cells promotes functional differentiation
por: Kawashima, Keigo, et al.
Publicado: (2021) -
Type I interferon, anti-interferon antibodies, and COVID-19
por: Calabrese, Leonard H, et al.
Publicado: (2021) -
COVID‑19 antibody production by vaccination in chemotherapy with CD20 antibody for B‑cell lymphoma
por: Tsutsumi, Yutaka, et al.
Publicado: (2023) -
Identification of a small molecule that primes the type I interferon response to cytosolic DNA
por: Khiar, Samira, et al.
Publicado: (2017)